Analysts Issue Forecasts for Rezolute FY2025 Earnings

Rezolute, Inc. (NASDAQ:RZLT) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Rezolute in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos expects that the company will post earnings of ($0.97) per share for the year. The consensus estimate for Rezolute’s current full-year earnings is ($0.99) per share.

Rezolute (NASDAQ:RZLT) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.13.

A number of other brokerages have also commented on RZLT. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 target price on shares of Rezolute in a research report on Friday, November 8th. Wedbush reaffirmed an “outperform” rating and issued a $112.00 target price on shares of Rezolute in a research report on Monday, November 4th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Rezolute has a consensus rating of “Buy” and a consensus target price of $24.13.

Rezolute Price Performance

Shares of Rezolute stock opened at $4.81 on Thursday. Rezolute has a one year low of $0.92 and a one year high of $6.19. The firm has a market capitalization of $278.69 million, a price-to-earnings ratio of -3.79 and a beta of 1.08. The business has a 50-day simple moving average of $4.88 and a 200 day simple moving average of $4.85.

Insiders Place Their Bets

In related news, CFO Daron Evans acquired 9,000 shares of the firm’s stock in a transaction on Thursday, December 12th. The stock was purchased at an average cost of $4.60 per share, with a total value of $41,400.00. Following the acquisition, the chief financial officer now owns 140,900 shares of the company’s stock, valued at approximately $648,140. This trade represents a 6.82 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 18.39% of the company’s stock.

Hedge Funds Weigh In On Rezolute

A number of hedge funds and other institutional investors have recently modified their holdings of RZLT. Dimensional Fund Advisors LP purchased a new position in shares of Rezolute in the 2nd quarter worth approximately $255,000. XTX Topco Ltd boosted its stake in shares of Rezolute by 205.8% in the 2nd quarter. XTX Topco Ltd now owns 33,671 shares of the company’s stock worth $145,000 after buying an additional 22,660 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of Rezolute in the 2nd quarter worth approximately $4,503,000. Cubist Systematic Strategies LLC boosted its stake in shares of Rezolute by 366.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 54,237 shares of the company’s stock worth $233,000 after buying an additional 42,597 shares during the last quarter. Finally, Affinity Asset Advisors LLC boosted its stake in shares of Rezolute by 15.6% in the 2nd quarter. Affinity Asset Advisors LLC now owns 1,850,000 shares of the company’s stock worth $7,955,000 after buying an additional 250,000 shares during the last quarter. Hedge funds and other institutional investors own 82.97% of the company’s stock.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.